VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

December, 12 2022

BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that management is scheduled to participate at the LifeSci Partners 12th Annual Corporate Access Event being held during the week of the J.P. Morgan Healthcare Conference, in San Francisco, CA and will be available for one-on-one meetings. One-on-One Meeting Details Meeting Dates: January 10-11, 2023 Location: Beacon Grand Hotel Format: 1-on-1, in-person meetings *For more information or to request a meeting please register here About VYNE…

Read More

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

December, 07 2022

BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that GB Patent No. 2597228 entitled “Compounds Comprising N-Methyl-2-Pyridone, And Pharmaceutically Acceptable Salts” has been granted by the United Kingdom’s Intellectual Property Office. This granted patent covers the compound in VYNE’s VYN201 program and has a 20-year term that will expire in April 2040. This newly issued patent is derived from The University of Dundee’s PCT application No. WO 2020/216779, which was filed nationally in multiple…

Read More

VYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

December, 02 2022

BRIDGEWATER, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference on December 8, 2022. Panel Presentation Details Date: Thursday, December 8, 2022 Time: 10:00 to 10:45 a.m. ET Panel Presentation: Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus Presenter: David Domzalski, President and Chief Executive Officer…

Read More